Purchase of Agilent 4150 Tape Station

The contract involves the acquisition of an Agilent 4150 Tape Station instrument, intended to support the integrated workflow for whole genome sequencing DNA and sample preparation tasks. This purchase is forecasted by the Food and Drug Administration and is aligned with the NAICS code 334516, indicating it falls under manufacture of analytical laboratory instrument manufacturing. The contract details emphasize the technical enhancement of genomic sequencing capabilities within the agency, seeking to improve the accuracy and efficiency of DNA sample analysis. The procurement process is currently in the forecast stage, with key organizational contacts identified to facilitate communication, including a designated program acquisition liaison and a contracting officer whose details have yet to be finalized. The opportunity is publicly accessible through the FDA’s industry opportunity forecast portal, although specific location details for the place of performance and office address remain unspecified. This investment reflects the FDA's continued commitment to advancing its laboratory instrumentation resources in support of genomic research and related biomedical applications.